HRP20170553T1 - Zaštita protiv disfunkcije endotelne barijere putem inhibicije gena povezanog s tirozin kinazom abl (arg) - Google Patents
Zaštita protiv disfunkcije endotelne barijere putem inhibicije gena povezanog s tirozin kinazom abl (arg) Download PDFInfo
- Publication number
- HRP20170553T1 HRP20170553T1 HRP20170553TT HRP20170553T HRP20170553T1 HR P20170553 T1 HRP20170553 T1 HR P20170553T1 HR P20170553T T HRP20170553T T HR P20170553TT HR P20170553 T HRP20170553 T HR P20170553T HR P20170553 T1 HRP20170553 T1 HR P20170553T1
- Authority
- HR
- Croatia
- Prior art keywords
- arg
- inhibitor
- abl
- function
- related gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims 16
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title claims 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title claims 6
- 230000004064 dysfunction Effects 0.000 title claims 4
- 230000008497 endothelial barrier function Effects 0.000 title claims 4
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 11
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 229960002411 imatinib Drugs 0.000 claims 5
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 5
- 206010030113 Oedema Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 238000013518 transcription Methods 0.000 claims 4
- 230000035897 transcription Effects 0.000 claims 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 3
- 206010037423 Pulmonary oedema Diseases 0.000 claims 3
- 230000015556 catabolic process Effects 0.000 claims 3
- 229960002448 dasatinib Drugs 0.000 claims 3
- 238000006731 degradation reaction Methods 0.000 claims 3
- 210000002889 endothelial cell Anatomy 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 229960001346 nilotinib Drugs 0.000 claims 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 3
- 208000005333 pulmonary edema Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000013171 endarterectomy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Inhibitor funkcije gena povezanog s Abl (ARG) za uporabu u liječenju pojedinca koja boluje od ili je u opasnosti oboliti od upalnog edema, pri tome je navedeni inhibitor odabran iz:
a) inhibitora aktivnosti tirozin kinaze proteina kodiranog navedenom Abl (ARG) povezanih gena odabranog iz nilotiniba ili njegove farmaceutski prihvatljive soli, dasatiniba ili njegove farmaceutski prihvatljive soli, i imatiniba ili njegove farmaceutski prihvatljive soli;
b) anti-ARG antitela koje veže ARG i inhibira funkciju; i
c) molekula nukleinske kiseline koji uzrokuje degradaciju ARG ili inhibira funkciju, transkripciju ili translaciju ARG.
2. Inhibitor za uporabu sukladno patentnom zahtjevu 1 naznačen time što navedeni upalni edem je edem prouzročen trombinom.
3. Inhibitor za uporabu sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time što navedeni pojedinac koji boluje od ili je u opasnosti oboliti od upalnog edema boluje od sepse, ALI/ARDS, preeklampsije, stenoze bez ponovnog protoka, plućnog edema i poželjno nakon zračenja plućnog edema ili plućnog edema poslije endarterektomije.
4. Inhibitor za uporabu sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačen time što navedeni inhibitor aktivnosti tirozin kinaze ne inhibira značajno aktivnost tirozin kinaze C-kit, PDGFR-alfa i/ili C-Abl.
5. Inhibitor za uporabu sukladno bilo kojem od patentnih zahtjeva 1-4, naznačen time što navedeni inhibitor funkcije gena povezanog s Abl (ARG) je imatinib ili njegova farmaceutski prihvatljiva sol.
6. Inhibitor za uporabu sukladno bilo kojem od patentnih zahtjeva 1-4, naznačen time što navedeni inhibitor funkcije gena povezanog s Abl (ARG) sadrži antisens oligonukleotid specifičnim za pre-iRNK kodiranu od strane navedenog gena povezanog s Abl (ARG).
7. Inhibitor za uporabu sukladno bilo kojem od patentnih zahtjeva 1-4, naznačen time što navedeni inhibitor funkcije gena povezanog s Abl (ARG) sadrži siRNK specifičnim za iRNK kodiranu od strane navedenog gena povezanog s Abl (ARG).
8. Inhibitor za uporabu sukladno bilo kojem od patentnih zahtjeva 1-7, naznačen time što je navedeni inhibitor funkcije gena povezanog s Abl (ARG) osiguran tijekom vremenskog razdoblja od između 1-20 tjedana.
9. Postupak za inhibiciju disfunkcije endotelne barijere u in vitro kolekciji endotelnih stanica koja sadrži endotelnu barijeru koja je u disfunkciji ili je u riziku od disfunkcije, pri čemu navedeni postupak sadrži osiguranje navedene kolekcije endotelnih stanica s inhibitorom funkcije gena povezanog s Abl (ARG), pri čemu je navedeni inhibitor odabran iz:
a) inhibitora aktivnosti tirozin kinaze proteina kodiranog od strane navedenog gena povezanog s Abl (ARG) odabranog od nilotiniba ili njegove farmaceutski prihvatljive soli, dasatiniba ili njegove farmaceutski prihvatljive soli, i imatiniba ili njegove farmaceutski prihvatljive soli;
b) anti-ARG antitijela koji veže ARG i inhibira funkciju; i
c) molekula nukleinske kiseline koji uzrokuje razlaganje ARG ili inhibira funkciju, transkripciju ili translaciju ARG.
10. Postupak sukladno patentnom zahtjevu 9, naznačen time što navedeni inhibitor funkcije gena povezanog s Abl (ARG) je imatinib ili njegova farmaceutski prihvatljiva sol.
11. Postupak sukladno patentnom zahtjevu 9, naznačen time što navedeni inhibitor funkcije gena povezanog s Abl (ARG) je molekula nukleinske kiseline koja uzrokuje razlaganje ARG ili inhibira funkciju, transkripciju ili translaciju ARG.
12. Zbirka endotelnih stanica koje sadrže endotelnu barijeru koja je u disfunkciji ili je u opasnosti od disfunkcije, pri čemu navedene stanice sadrže inhibitor funkcije gena povezanog s Abl (ARG), pri tome je navedeni inhibitor odabran iz:
a) inhibitora aktivnosti tirozin kinaze proteina kodiranog od strane navedenog gena povezanog s Abl (ARG) odabranog od nilotiniba ili njegove farmaceutski prihvatljive soli, dasatiniba ili njegove farmaceutski prihvatljive soli, i imatiniba ili njegove farmaceutski prihvatljive soli;
b) anti-ARG antitijela koje veže ARG i inhibira funkciju; i
c) molekula nukleinske kiseline koji uzrokuje razlaganje ARG ili inhibira funkciju, transkripciju ili translaciju ARG.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11731142.3A EP2717883B1 (en) | 2011-05-02 | 2011-05-02 | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
| PCT/NL2011/050299 WO2012150857A1 (en) | 2011-05-02 | 2011-05-02 | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170553T1 true HRP20170553T1 (hr) | 2017-06-02 |
Family
ID=44583314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170553TT HRP20170553T1 (hr) | 2011-05-02 | 2017-04-05 | Zaštita protiv disfunkcije endotelne barijere putem inhibicije gena povezanog s tirozin kinazom abl (arg) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9290765B2 (hr) |
| EP (1) | EP2717883B1 (hr) |
| DK (1) | DK2717883T3 (hr) |
| ES (1) | ES2622112T3 (hr) |
| HR (1) | HRP20170553T1 (hr) |
| LT (1) | LT2717883T (hr) |
| PL (1) | PL2717883T3 (hr) |
| PT (1) | PT2717883T (hr) |
| SI (1) | SI2717883T1 (hr) |
| WO (1) | WO2012150857A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2717883B1 (en) | 2011-05-02 | 2017-03-22 | Stichting VUmc | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
| CN109512805B (zh) | 2012-05-08 | 2021-12-31 | 埃罗米克斯公司 | 用于治疗水通道蛋白介导的疾病的化合物 |
| JP6535338B2 (ja) | 2013-11-06 | 2019-06-26 | エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． | 新規製剤 |
| WO2018013912A1 (en) * | 2016-07-15 | 2018-01-18 | The Board Of Regents Of The University Of Oklahoma | Anti-arid3a treatments for inflammatory disorders |
| CN112852853B (zh) * | 2021-01-08 | 2023-06-02 | 重庆医科大学附属儿童医院 | 一种高强度聚焦超声生物靶向增效剂及运用 |
| EP4046639A1 (en) | 2021-02-22 | 2022-08-24 | Stichting VUmc | Prevention of pulmonary vascular leak in covid-19 |
| GB202204070D0 (en) * | 2022-03-23 | 2022-05-04 | Exvastat Ltd | Treatment |
| US11752152B1 (en) | 2022-04-25 | 2023-09-12 | Exvastat Ltd | Pharmaceutical formulations of imatinib and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US6774288B1 (en) | 1997-07-07 | 2004-08-10 | Basf Plant Science L.L.C. | Animal feed with low phytic acid, oil, burdened and protein laden grain |
| MXPA01010292A (es) | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| US7846906B2 (en) | 2003-02-28 | 2010-12-07 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| WO2005047505A2 (en) | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
| WO2008147837A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas |
| UA100253C2 (uk) | 2007-11-26 | 2012-12-10 | Сантаріс Фарма А/С | Lna-антагоністи андрогенного рецептора |
| EP2717883B1 (en) | 2011-05-02 | 2017-03-22 | Stichting VUmc | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
-
2011
- 2011-05-02 EP EP11731142.3A patent/EP2717883B1/en active Active
- 2011-05-02 US US14/115,279 patent/US9290765B2/en active Active
- 2011-05-02 DK DK11731142.3T patent/DK2717883T3/en active
- 2011-05-02 WO PCT/NL2011/050299 patent/WO2012150857A1/en active Application Filing
- 2011-05-02 SI SI201131153A patent/SI2717883T1/sl unknown
- 2011-05-02 PT PT117311423T patent/PT2717883T/pt unknown
- 2011-05-02 ES ES11731142.3T patent/ES2622112T3/es active Active
- 2011-05-02 LT LTEP11731142.3T patent/LT2717883T/lt unknown
- 2011-05-02 PL PL11731142T patent/PL2717883T3/pl unknown
-
2017
- 2017-04-05 HR HRP20170553TT patent/HRP20170553T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2717883T1 (sl) | 2017-06-30 |
| WO2012150857A1 (en) | 2012-11-08 |
| EP2717883B1 (en) | 2017-03-22 |
| ES2622112T3 (es) | 2017-07-05 |
| EP2717883A1 (en) | 2014-04-16 |
| US9290765B2 (en) | 2016-03-22 |
| PT2717883T (pt) | 2017-04-19 |
| DK2717883T3 (en) | 2017-04-24 |
| US20140187605A1 (en) | 2014-07-03 |
| LT2717883T (lt) | 2017-04-25 |
| PL2717883T3 (pl) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170553T1 (hr) | Zaštita protiv disfunkcije endotelne barijere putem inhibicije gena povezanog s tirozin kinazom abl (arg) | |
| SMT201600164B (it) | Nuove n-acil-5, 6, 7, ( 8-s0stituito )-tetraidro-[1, 2, 4]triazolo[4, 3-a]pirazine chirali come antagonisti selettivi del recettore nk-3, composizione farmaceutica, e metodi per l'uso in disturbi mediati dal recettore nk-3 | |
| CL2014001729A1 (es) | Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer. | |
| EP3418386A3 (en) | Compositions and methods for inhibiting gene expression of hepatitis b virus | |
| ZA201404273B (en) | 2',4'-diflouro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| EA201492176A1 (ru) | Селективные ингибиторы pi3k дельта | |
| EP4279610A3 (en) | Ribonucleic acid purification | |
| WO2008151631A3 (en) | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis | |
| EP4124657A3 (en) | Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna | |
| CL2015001678A1 (es) | Compuestos derivados de 4-{7-metil-3-oxo-8-[3-(trifluoromeil)ciclohexa-2,4-dien-1-il]-2,3,5,8-tetrahidro[1,2,4]triazolo[4,3-a]pirimidin-5-il}benzonitrilo; composicion farmaceutica; un metodo para tratar una enfermedad o una afeccion en la que participa hne, tal como epoc, neumonia, asma, rinitis, entre otras. | |
| CL2014001070A1 (es) | Compuestos derivados de aminoácidos funcionalizados en el n-terminal, capaces de formar micro- o nanopartículas para encapsular un agente; composición; uso para tratar enfermedades; y método de suministro de un polinucleótido a una célula. | |
| WO2016061232A3 (en) | Multiplexed shrnas and uses thereof | |
| MX2013003938A (es) | Metodos y composiciones para inhibicion de polimerasa. | |
| WO2004078940A8 (en) | USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1 | |
| WO2011100550A3 (en) | Compositions and methods for treating depression | |
| MX351059B (es) | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. | |
| WO2012125981A3 (en) | Raf kinase inhibitors | |
| JP2018517660A5 (hr) | ||
| RU2019101864A (ru) | Фармацевтическая композиция для лечения недержания мочи и способ ее применения | |
| MX2014006015A (es) | Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1. | |
| WO2011054939A3 (en) | Compositions and methods for inhibiting expression of kif10 genes | |
| CL2014001155A1 (es) | Metodo para reducir el acido urico en el suero de un sujeto con hiperuricemia, administrando un primer agente reductor de urato y un segundo agente reductor de urato; composicion farmaceutica; kit farmaceutico; uso en el tratamiento de gota aguda, cronica, moderada, refractaria o severa. | |
| FR2927331B1 (fr) | Nouveaux derives anti-infectieux, leur procede de preparation, compositions pharmaceutiques les contenant et leurs utilisations en therapeutique. | |
| WO2012100172A3 (en) | Methods and compositions for the specific inhibition of hif-1a by double stranded rna | |
| FR3013058B1 (fr) | Procede dynamique d'elimination partielle ou totale de composes organohalogenes contenus dans des boissons, notamment dans du vin |